Experimental biology 2006: advancing the biomedical frontier.
Edwards
Catherine
C
Thomson Scientific, Holbrook House, 14 Great Queen Street, London, WC2B 5DF, UK. cathy.edwards@thomson.com
D058909:Adenosine A3 Receptor Agonists; D017667:Adipocytes / Q000166:cytology / Q000187:drug effects; D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000494:pharmacology*; D002454:Cell Differentiation; D003863:Depression / Q000188:drug therapy; D004195:Disease Models, Animal; D018492:Dopamine Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D005663:Furans / Q000494:pharmacology; D006801:Humans; D009043:Motor Activity / Q000187:drug effects; D015428:Myocardial Reperfusion Injury / Q000378:metabolism / Q000517:prevention & control; D009765:Obesity / Q000188:drug therapy; D011687:Purines / Q000494:pharmacology; D043684:Receptor, Adenosine A3 / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy
D058909:Adenosine A3 Receptor Agonists; D019440:Anti-Obesity Agents; C479779:CP-532,903; D002316:Cardiotonic Agents; D018492:Dopamine Antagonists; D018765:Dopamine Uptake Inhibitors; D005663:Furans; D011687:Purines; D043684:Receptor, Adenosine A3